Detalhe da pesquisa
1.
Atezolizumab for First-Line Treatment of PD-L1-Selected Patients with NSCLC.
N Engl J Med
; 383(14): 1328-1339, 2020 10 01.
Artigo
Inglês
| MEDLINE | ID: mdl-32997907
2.
USP7 small-molecule inhibitors interfere with ubiquitin binding.
Nature
; 550(7677): 534-538, 2017 10 26.
Artigo
Inglês
| MEDLINE | ID: mdl-29045385
3.
Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial.
Lancet
; 398(10308): 1344-1357, 2021 10 09.
Artigo
Inglês
| MEDLINE | ID: mdl-34555333
4.
Microenvironmental regulation of tumour immunity and response to immunotherapy.
J Pathol
; 254(4): 374-383, 2021 07.
Artigo
Inglês
| MEDLINE | ID: mdl-33846997
5.
An integrative analysis of colon cancer identifies an essential function for PRPF6 in tumor growth.
Genes Dev
; 28(10): 1068-84, 2014 May 15.
Artigo
Inglês
| MEDLINE | ID: mdl-24788092
6.
Metabolic plasticity underpins innate and acquired resistance to LDHA inhibition.
Nat Chem Biol
; 12(10): 779-86, 2016 10.
Artigo
Inglês
| MEDLINE | ID: mdl-27479743
7.
Cdk8 deletion in the Apc(Min) murine tumour model represses EZH2 activity and accelerates tumourigenesis.
J Pathol
; 237(4): 508-19, 2015 Dec.
Artigo
Inglês
| MEDLINE | ID: mdl-26235356
8.
Comparison of SP263 and 22C3 immunohistochemistry PD-L1 assays for clinical efficacy of adjuvant atezolizumab in non-small cell lung cancer: results from the randomized phase III IMpower010 trial.
J Immunother Cancer
; 11(10)2023 10.
Artigo
Inglês
| MEDLINE | ID: mdl-37903590
9.
Comparison of SP142 and 22C3 Immunohistochemistry PD-L1 Assays for Clinical Efficacy of Atezolizumab in Non-Small Cell Lung Cancer: Results From the Randomized OAK Trial.
Clin Lung Cancer
; 23(1): 21-33, 2022 01.
Artigo
Inglês
| MEDLINE | ID: mdl-34226144
10.
Clinical efficacy of atezolizumab plus bevacizumab and chemotherapy in KRAS-mutated non-small cell lung cancer with STK11, KEAP1, or TP53 comutations: subgroup results from the phase III IMpower150 trial.
J Immunother Cancer
; 10(2)2022 02.
Artigo
Inglês
| MEDLINE | ID: mdl-35190375
11.
RNAi of mitotic cyclins in Drosophila uncouples the nuclear and centrosome cycle.
Curr Biol
; 18(4): 245-54, 2008 Feb 26.
Artigo
Inglês
| MEDLINE | ID: mdl-18291653
12.
Updated Overall Survival Analysis From IMpower110: Atezolizumab Versus Platinum-Based Chemotherapy in Treatment-Naive Programmed Death-Ligand 1-Selected NSCLC.
J Thorac Oncol
; 16(11): 1872-1882, 2021 11.
Artigo
Inglês
| MEDLINE | ID: mdl-34265434
13.
IMpower150 Final Overall Survival Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in First-Line Metastatic Nonsquamous NSCLC.
J Thorac Oncol
; 16(11): 1909-1924, 2021 11.
Artigo
Inglês
| MEDLINE | ID: mdl-34311108
14.
NRF2 Activation Promotes Aggressive Lung Cancer and Associates with Poor Clinical Outcomes.
Clin Cancer Res
; 27(3): 877-888, 2021 02 01.
Artigo
Inglês
| MEDLINE | ID: mdl-33077574
15.
Atezolizumab Plus Chemotherapy for First-Line Treatment of Nonsquamous NSCLC: Results From the Randomized Phase 3 IMpower132 Trial.
J Thorac Oncol
; 16(4): 653-664, 2021 04.
Artigo
Inglês
| MEDLINE | ID: mdl-33333328
16.
Molecular determinants of response to PD-L1 blockade across tumor types.
Nat Commun
; 12(1): 3969, 2021 06 25.
Artigo
Inglês
| MEDLINE | ID: mdl-34172722
17.
Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133).
J Clin Oncol
; 39(6): 619-630, 2021 02 20.
Artigo
Inglês
| MEDLINE | ID: mdl-33439693
18.
Intratumoral CD103+ CD8+ T cells predict response to PD-L1 blockade.
J Immunother Cancer
; 9(4)2021 04.
Artigo
Inglês
| MEDLINE | ID: mdl-33827905
19.
Atezolizumab in combination with bevacizumab, paclitaxel and carboplatin for the first-line treatment of patients with metastatic non-squamous non-small cell lung cancer, including patients with EGFR mutations.
Expert Rev Respir Med
; 14(2): 125-136, 2020 02.
Artigo
Inglês
| MEDLINE | ID: mdl-31829747
20.
Atezolizumab in Combination With Carboplatin and Nab-Paclitaxel in Advanced Squamous NSCLC (IMpower131): Results From a Randomized Phase III Trial.
J Thorac Oncol
; 15(8): 1351-1360, 2020 08.
Artigo
Inglês
| MEDLINE | ID: mdl-32302702